Immunoglobulin variants
AssigneeGenentech, Inc.
InventorsPaul J. Carter, Leonard G. Presta
Life of this patent
Estimating the term…
Abstract
Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.
Claims15
A humanized antibody comprising the light chain variable domain sequence in SEQ ID NO:
- 17.
A humanized antibody comprising the heavy chain variable domain sequence in SEQ ID NO:
- 20.
A humanized anti-CD3 antibody comprising the amino acid sequences in SEQ ID NO:
- 17 and SEQ ID NO:
- 20.
A variable domain of a humanized antibody comprising a heavy chain variable domain amino acid sequence within a sequence selected from the group consisting of:
- SEQ ID NO:
- 23;
- SEQ ID NO:
- 26;
- SEQ ID NO:
- 27;
- SEQ ID NO:
- 28;
- SEQ ID NO:
- 29;
- SEQ ID NO:
- 30;
- SEQ ID NO:
- 31;
- SEQ ID NO:
- 32;
- SEQ ID NO:
- 33;
- SEQ ID NO:
- 34;
- SEQ ID NO:
- 35;
- SEQ ID NO:
- 36;
- SEQ ID NO:
- 37;
- and SEQ ID NO:
- 38.
A variable domain of a humanized antibody comprising a light chain variable domain amino acid sequence within a sequence selected from the group consisting of SEQ ID NO:
- 25;
- SEQ ID NO:
- 39;
- and SEQ ID NO:
- 40.
A humanized anti-CD18 antibody comprising the variable domain sequence in SEQ ID NO:
- 46 and the variable domain sequence in SEQ ID NO:
- 47.
A polypeptide comprising the following amino acid sequence:
- __________________________________________________________________________ DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLX.sup.1 SGVPSRFS GSX.sup.2 SGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID __________________________________________________________________________ NO:43),
- wherein X.sup.1 is E or Y and X.sup.2 is R or G.
A polypeptide comprising the following amino acid sequence:
- __________________________________________________________________________ EVQLVESGGGLVQPGGSLRLSCMSGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADS RFTISX.sup.3 DX.sup.4 SKNTX.sup.5 YLQMNSLRAEDTAVYYCX.sup.6 RWGGDGFYAMDX.su p.7 WGQGTLVTVSS SEQ ID NO:44), __________________________________________________________________________
- wherein X.sup.3 is A or R, X.sup.4 is T or D, X.sup.5 is A or L, X.sup.6 is S or A and X.sup.7 is V or Y.
A humanized antibody comprising the heavy chain variable domain sequence:
- __________________________________________________________________________ EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSV KGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDX.sup.1 WGQGTLVTVSS (SEQ ID NO:48), __________________________________________________________________________
- wherein X.sup.1 is V or Y, and wherein the humanized antibody binds p185.sup.HER2 more tightly than the non-human import antibody from which the CDR amino acid residues of the humanized antibody are derived.
A humanized anti-HER2 antibody which comprises the light chain variable domain amino acid sequence:
- __________________________________________________________________________ DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGS RSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:41) __________________________________________________________________________
- and the heavy chain variable domain amino acid sequence:
- __________________________________________________________________________ EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSV KGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS (SEQ ID NO:42). __________________________________________________________________________
Dependencies are inferred from the claim text.